Sertindole, a Potent Antagonist at Dopamine D2 Receptors, Induces Autophagy by Increasing Reactive Oxygen Species in SH-SY5Y Neuroblastoma Cells

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 7, 2012, Pages 1069-1075

  Shin, Ji Hyun ^a   Park, So Jung ^a   Kim, Eun Sung ^a   Jo, Yoon Kyung ^a   Hong, Jungwoo ^a   Cho, Dong Hyung ^a  

^a Kyung Hee University   (South Korea)

Author keywords

ATG5; Autophagy; Reactive oxygen species; Sertindole; SH SY5Y cell

Indexed keywords

AUTOPHAGY PROTEIN 5; REACTIVE OXYGEN METABOLITE; SERTINDOLE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; MOUSE; NEUROBLASTOMA CELL; NONHUMAN;

ACETYLCYSTEINE; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CHROMANS; HUMANS; IMIDAZOLES; INDOLES; NEUROBLASTOMA; REACTIVE OXYGEN SPECIES; RECEPTORS, DOPAMINE D2;

EID: 84863556708     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00009     Document Type: Article

References (41)

1. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol., 8, 931-937 (2007).
2. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell, 147, 728-741 (2011).
3. Sridhar S, Botbol Y, Macian F, Cuervo AM. Autophagy and disease: always two sides to a problem. J. Pathol., 226, 255-273 (2012).
4. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature, 451, 1069-1075 (2008).
5. Bové J, Martínez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci., 12, 437-452 (2011).
6. Lista P, Straface E, Brunelleschi S, Franconi F, Malorni W. On the role of autophagy in human diseases: a gender perspective. J. Cell. Mol. Med., 15, 1443-1457 (2011).
7. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, Yuan J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl. Acad. Sci. U.S.A., 104, 19023-19028 (2007).
8. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG, Nabi IR, Roberge M. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE, 4, e7124 (2009).
9. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, O'Kane CJ, Floto RA, Rubinsztein DC. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol., 4, 295-305 (2008).
10. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat. Chem. Biol., 7, 9-17 (2011).
11. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim. Biophys. Acta, 1806, 220-229 (2010).
12. Duan J, Sanders AR, Gejman PV. Genome-wide approaches to schizophrenia. Brain Res. Bull., 83, 93-102 (2010).
13. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR, Mirel DB, Kendler KS, Freedman R, Gejman PV. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature, 460, 753-757 (2009).
14. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Genetic Risk and Outcome in Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA. Common variants conferring risk of schizophrenia. Nature, 460, 744-747 (2009).
15. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jönsson EG, Bitter I, Pietiläinen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genomewide association study identifies five new schizophrenia loci. Nat. Genet., 43, 969-976 (2011).
16. Freedman R. Schizophrenia. N. Engl. J. Med., 349, 1738-1749 (2003).
17. Freedman R. The choice of antipsychotic drugs for schizophrenia. N. Engl. J. Med., 353, 1286-1288 (2005).
18. Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin. Drug Metab. Toxicol., 4, 629-638 (2008).
19. Kasper S, Möller HJ, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur. Arch. Psychiatry Clin. Neurosci., 260, 59-68 (2010).
20. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J. Pharmacol. Exp. Ther., 286, 788-793 (1998).
21. Kang J, Chen XL, Rampe D. The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel. Biochem. Biophys. Res. Commun., 286, 499-504 (2001).
22. Hosokawa N, Hara Y, Mizushima N. Generation of cell lines with tetracycline-regulated autophagy and a role for autophagy in controlling cell size. FEBS Lett., 580, 2623-2629 (2006).
23. Jo YK, Park SJ, Shin JH, Kim Y, Hwang JJ, Cho DH, Kim JC. ARP101, a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells. Biochem. Biophys. Res. Commun., 404, 1039-1043 (2011).
24. Park SJ, Shin JH, Kang H, Hwang JJ, Cho DH. Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep, 44, 517-522 (2011).
25. Muscatello MR, Bruno A, Pandolfo G, Micò U, Settineri S, Zoccali R. Emerging treatments in the management of schizophrenia-focus on sertindole. Drug Des Devel Ther, 4, 187-201 (2010).
26. Horesh Y, Katsel P, Haroutunian V, Domany E. Gene expression signature is shared by patients with Alzheimer's disease and schizophrenia at the superior temporal gyrus. Eur. J. Neurol., 18, 410-424 (2011).
27. Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy, 4, 1079-1082 (2008).
28. Eng CH, Abraham RT. Glutaminolysis yields a metabolic by-product that stimulates autophagy. Autophagy, 6, 968-970 (2010).
29. Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol. Psychiatry, 69, 19-27 (2011).
30. Hattori A, Luo Y, Umegaki H, Munoz J, Roth GS. Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport, 9, 2569-2572 (1998).
31. Gómez-Santos C, Ferrer I, Santidrián AF, Barrachina M, Gil J, Ambrosio S. Dopamine induces autophagic cell death and alphasynuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res., 73, 341-350 (2003).
32. Bozzi Y, Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci., 29, 167-174 (2006).
33. Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol. Dis., 42, 391-403 (2011).
34. Kitamura Y, Taniguchi T, Shimohama S, Akaike A, Nomura Y. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem. Res., 28, 1035-1040 (2003).
35. Ferrari-Toninelli G, Bonini SA, Cenini G, Maccarinelli G, Grilli M, Uberti D, Memo M. Dopamine receptor agonists for protection and repair in Parkinson's disease. Curr. Top. Med. Chem., 8, 1089-1099 (2008).
36. Amano T, Ujihara H, Matsubayashi H, Sasa M, Yokota T, Tamura Y, Akaike A. Dopamine-induced protection of striatal neurons against kainate receptor-mediated glutamate cytotoxicity in vitro. Brain Res., 655, 61-69 (1994).
37. Noh JS, Gwag BJ. Attenuation of oxidative neuronal necrosis by a dopamine D1 agonist in mouse cortical cell cultures. Exp. Neurol., 146, 604-608 (1997).
38. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res., 657, 207-213 (1994).
39. Armando I, Wang X, Villar VA, Jones JE, Asico LD, Escano C, Jose PA. Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. Hypertension, 49, 672-678 (2007).
40. Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem. Sci., 36, 30-38 (2011).
41. Huang J, Lam GY, Brumell JH. Autophagy signaling through reactive oxygen species. Antioxid. Redox Signal., 14, 2215-2231 (2011).